Skip to main content
Year archive

Xspray Pharma — 2020 filings

All 37 regulatory filings released by Xspray Pharma (XSPRAY) in 2020, sourced directly from the official regulator.

37 Filings
2020 Period
2020 filings (37)
Filing Released Lang
Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia
Regulatory Filings
2020-12-29 English
Xspray Pharmas HyNap-Nilo erhåller särläkemedelsstatus från FDA för behandling av kronisk myeloisk leukemi
Regulatory Filings
2020-12-29 Swedish
Xspray Pharma har beslutat att invänta resultaten från två pågående kliniska studier innan ANDA-ansökan lämnas in
Regulatory Filings
2020-12-11 Swedish
Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application
Regulatory Filings
2020-12-11 English
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-11-20 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-11-20 English
Antal aktier och röster i Xspray
Declaration of Voting Results & Voting Rights Announcements
2020-10-30 Swedish
Number of shares and votes in Xspray
Share Issue/Capital Change
2020-10-30 English
Xspray Pharma Has Carried Out a Directed Share Issue Raising Gross Proceeds of Approximately SEK 265 million
Capital/Financing Update
2020-10-20 English
Xspray Pharma har genomfört en riktad emission som tillför bolaget cirka 265 MSEK
Capital/Financing Update
2020-10-20 Swedish
Xspray Pharma överväger en riktad emission
Capital/Financing Update
2020-10-20 Swedish
Xspray Pharma Contemplates a Directed Share Issue
Capital/Financing Update
2020-10-20 English
Antal aktier och röster i Xspray
Share Issue/Capital Change
2020-09-30 Swedish
Number of shares and votes in Xspray
Share Issue/Capital Change
2020-09-30 English
Xspray announces positive preliminary results from the study for its lead product candidate HyNap-Dasa
Earnings Release FY 2020
2020-09-25 English
Xspray meddelar positiva preliminära resultat från studien för sin ledande produktkandidat HyNap-Dasa
Report Publication Announcement
2020-09-25 Swedish
Michael Wolff Jensen will not stand for re-election as Chairman of Xspray Pharma AB
Board/Management Information
2020-09-21 English
Michael Wolff Jensen avstår omval som ordförande för Xspray Pharma AB
Board/Management Information
2020-09-21 Swedish
Number of shares and votes in Xspray
Share Issue/Capital Change
2020-08-31 English
Antal aktier och röster i Xspray
Declaration of Voting Results & Voting Rights Announcements
2020-08-31 Swedish
Warrant holders exercise all warrants within the framework of incentive program
Remuneration Information
2020-08-21 English
Optionsinnehavare utnyttjar samtliga teckningsoptioner inom ramen för incitamentsprogram
Share Issue/Capital Change
2020-08-21 Swedish
Xspray strengthens the value of the product portfolio with patent protection for tablet of dasatinib propylene glycol solvate
Regulatory Filings
2020-08-18 English
Xspray stärker värdet på produktportföljen med patent för dasatinib propylenglykolsolvat tablett
Regulatory Filings
2020-08-18 Swedish
Xspray meddelar preliminära resultat från den första studien för sin ledande produktkandidat HyNap-Dasa
Regulatory Filings
2020-08-12 Swedish
Xspray announces preliminary results from the first study for its lead product candidate HyNap-Dasa
Regulatory Filings
2020-08-12 English
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-07-31 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-07-31 English
Xspray Pharma initiates pivotal registration studies with HyNap-Dasa for the market approval application in the United States
Regulatory Filings
2020-05-29 English
Xspray Pharma inleder registreringsgrundande kliniska studier med HyNap-Dasa för ansökan om marknadsgodkännande i USA
Report Publication Announcement
2020-05-29 Swedish
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
AGM Information
2020-05-14 English
Kommuniké från årsstämma i Xspray Pharma AB (publ)
AGM Information
2020-05-14 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-14 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-14 Swedish
Xspray Phama ger en uppdatering om covid-19-pandemins inverkan på bolagets planerade kliniska studier
Regulatory Filings
2020-04-15 Swedish
Xspray Pharma provides an update on how the Covid-19 pandemic affects the company’s planned clinical studies
Regulatory Filings
2020-04-15 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-03-31 English